Corbus Pharmaceuticals will host an in-person and virtual event at ASCO 2026 to present updated Phase 1/2 data on CRB-701, a next-gen antibody-drug conjugate for head and neck squamous cell carcinoma (HNSCC). The data includes clinical response durability and patient subgroup analysis from 75 participants. The event features leading oncology experts and follows recent FDA alignment on CRB-701's regulatory path. This presentation highlights Corbus's progress in developing innovative cancer therapies targeting Nectin-4 expressing tumors.
Zoom Video Communications will release its Q3 2026 earnings on August 25, with analysts expecting $1.48 EPS and $1.27 billion revenue. Despite a slight EPS decline from last year, Zoom has a strong track record of surpassing earnings estimates in nin...
Roth Capital increased its price target for nVent Electric to $195 from $185, citing strong growth potential driven by the company's planned $1.75 billion acquisition of Maverick Power. This deal aims to expand nVent's offerings in the growing data c...
Snowflake, a leading cloud data platform, is showing strong market momentum with analysts maintaining a Buy rating and raising price targets from $290 to $360. Despite a recent 3% dip, its stock has surged over 24% in the past month, outperforming th...
Dick's Sporting Goods reported quarterly earnings with an EPS of $3.53, below the expected $3.76, and revenue that also missed Wall Street forecasts. The shortfall is partly due to the Foot Locker acquisition, which lowered EPS and led to a reduced f...
Semtech Corporation is set to report strong Q2 earnings with an expected EPS of $0.61, up from $0.41 last year, and projected revenue of $328.67 million, a 27.5% increase driven by demand in data centers and its LoRa technology. The company recently ...
